TL;DR
This study investigated whether common heartburn medications, proton-pump inhibitors (PPIs), negatively impact the survival outcomes of Chinese men with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) treated with docetaxel and androgen deprivation therapy (ADT). The findings suggest that PPI use is associated with poorer overall survival, highlighting a potential drug-drug interaction that warrants clinical consideration.
What Problem Does This Paper Address?
Prostate cancer is a significant global health concern. While treatments like androgen deprivation therapy (ADT) and chemotherapy (docetaxel, DOC) have improved outcomes for metastatic hormone-sensitive prostate cancer (mHSPC), the influence of commonly prescribed co-medications on treatment efficacy is an area of ongoing research. Proton-pump inhibitors (PPIs), widely used for gastrointestinal issues, have been implicated in drug-drug interactions with other cancer therapies, particularly abiraterone. However, the impact of PPIs on patients receiving DOC and ADT, a standard upfront treatment for mHSPC, remained largely unexplored. This paper aims to fill that knowledge gap by examining whether PPI use affects survival in this specific patient population.
Methods
The researchers conducted a retrospective analysis of a prospectively maintained database from the Hong Kong Prostate Cancer Study Group. They identified 101 patients diagnosed with de novo mHSPC between 2016 and 2022 who received upfront docetaxel (within 6 months of ADT initiation). Patients were categorized into two groups: those using PPIs at the start of ADT and those not using PPIs. A landmark analysis was performed at 6 months post-treatment initiation. Key outcomes assessed included overall survival (OS), castration-resistant prostate cancer (CRPC)-free survival, and cancer-specific survival (CSS), along with PSA kinetics (e.g., time to PSA nadir, proportion achieving specific PSA reductions). Statistical analyses included Kaplan-Meier survival curves, log-rank tests, and multivariate Cox regression to identify independent predictors of survival, controlling for factors like age and PSA levels.
Datasets
The study utilized data from the Hong Kong Prostate Cancer Study Group Database, a prospective registry of prostate cancer patients diagnosed across five hospitals in Hong Kong. This database was registered on ClinicalTrials.gov (NCT03344835). No new datasets were introduced.
Key Insights and Ideas
- PPIs as a Potential Obstacle: The study provides evidence suggesting that PPIs, commonly used for managing treatment-related side effects or pre-existing conditions, might interfere with the effectiveness of standard mHSPC treatment regimens involving docetaxel and ADT.
- Early Survival Differences: The Kaplan-Meier curves indicated that survival differences between PPI users and non-users began to emerge relatively early in the treatment course, suggesting a potential impact beyond just late-stage disease progression.
- Molecular Mechanisms Speculated: While the study is observational, the authors discuss potential molecular mechanisms for PPI interference, including direct effects on cancer cell proliferation, induction of cell-cycle progression, and alteration of the gut microbiome, which has been linked to treatment response.
- Clinical Caution Advised: The findings underscore the need for clinicians to carefully consider the indication for PPI use in mHSPC patients undergoing systemic therapy and hormonal treatment, suggesting that PPIs should only be used when strictly necessary.
Key Results
- Survival Impact: Patients using PPIs had significantly worse overall survival (OS) compared to non-users. The hazard ratio for OS in PPI users was 2.28 (95% CI: 1.112–4.675, p = 0.025).
- PSA Nadir: A higher proportion of patients in the non-PPI group achieved a PSA nadir of <0.1 ng/mL (19.0% vs. 4.5%, p = 0.041), indicating potentially better cancer control.
- Multivariate Significance: In multivariate regression analysis, PPI usage was identified as the only statistically significant factor associated with poorer OS (p = 0.036).
- Cohort Characteristics: The study included 101 patients (79 non-PPI, 22 PPI), with similar baseline characteristics. All patients had high-risk and high-volume disease.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Nature: The study design is retrospective, which inherently limits the ability to establish causality and control for all potential confounding factors.
- Observational Study: As an observational study, it cannot definitively prove that PPIs cause the poorer outcomes, only that they are associated.
- Small Sample Size: The relatively small sample size, particularly in the PPI group (n=22), may limit the generalizability of the findings and affect the robustness of the statistical power.
- Lack of Specific PPI Data: The study did not account for the duration of PPI use, route of administration, or specific types of PPIs used, which could influence outcomes.
- Undetermined Clinical Indications: The exact clinical reasons for PPI use in individual patients were not determined, which could be a confounder.
- Future Directions: The authors emphasize the need for further high-quality clinical and mechanistic data to elucidate the precise drug-drug interactions between PPIs and docetaxel. They suggest that future research should focus on establishing causal relationships and exploring alternative strategies or deprescribing PPIs when appropriate, in consultation with clinicians.
Summary updated